Adaptive Biotechnologies Stock Price, News & Analysis (NASDAQ:ADPT) $4.38 -0.24 (-5.19%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$4.31▼$4.7050-Day Range$3.46▼$5.6452-Week Range$2.61▼$10.79Volume1.38 million shsAverage Volume1.16 million shsMarket Capitalization$634.09 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Adaptive Biotechnologies MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside116.9% Upside$9.50 Price TargetShort InterestBearish7.76% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1,070 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.35) to ($1.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector534th out of 949 stocksBiological Products, Except Diagnostic Industry87th out of 163 stocks 3.2 Analyst's Opinion Consensus RatingAdaptive Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Adaptive Biotechnologies has a forecasted upside of 116.9% from its current price of $4.38.Amount of Analyst CoverageAdaptive Biotechnologies has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.76% of the outstanding shares of Adaptive Biotechnologies have been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 4.56%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAdaptive Biotechnologies has received a 61.36% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Basic medical research services", "Scientific databases", and "Medical laboratory automation systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Adaptive Biotechnologies is -0.79. Previous Next 2.2 News and Social Media Coverage News SentimentAdaptive Biotechnologies has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Adaptive Biotechnologies this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for ADPT on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -72% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions94.31% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.35) to ($1.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -3.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adaptive Biotechnologies Stock (NASDAQ:ADPT)Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Read More ADPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADPT Stock News HeadlinesNovember 22, 2023 | bizjournals.comAdaptive Biotechnologies eyes 'strategic alternatives' for its 2 businessesNovember 22, 2023 | finance.yahoo.comADPT Nov 2016 40.000 putDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 17, 2023 | finance.yahoo.comAnalysts Just Slashed Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) EPS NumbersNovember 16, 2023 | markets.businessinsider.comScotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)November 10, 2023 | finance.yahoo.comAdaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | marketwatch.comAdaptive Biotechnologies Shares Fall 35% After Reviewing AlternativesNovember 10, 2023 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)December 1, 2023 | Tomorrow Investor (Ad)Why Microsoft Just Placed A Huge Bet On NuclearEven with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.November 9, 2023 | seekingalpha.comAdaptive Biotechnologies Corporation 2023 Q3 - Results - Earnings Call PresentationNovember 9, 2023 | finance.yahoo.comAdaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 7, 2023 | finance.yahoo.comAdaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy PipelineNovember 2, 2023 | finance.yahoo.comAdaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023October 26, 2023 | finance.yahoo.comAdaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOctober 18, 2023 | onmsft.comXbox Adaptive Controller to get keyboard and mouse remapping and other featuresOctober 11, 2023 | msn.comAdaptive Biotechnologies (ADPT) Price Target Increased by 5.86% to 12.82September 27, 2023 | msn.comAdaptive Biotechnologies: Not Quite There Yet, Growth Looks PricedSeptember 27, 2023 | finance.yahoo.comStrength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?September 26, 2023 | markets.businessinsider.comWhat's Going On With Adaptive Biotechnologies (ADPT) Stock?September 26, 2023 | macrumors.comApple Initially Explored Using GPS to Control AirPods Pro Adaptive AudioSeptember 17, 2023 | msn.comRock Island Parks and Recreation hosts Adaptive BaseballSeptember 13, 2023 | yahoo.comJesse Billauer Takes First Place in Adaptive Surfing ChampionshipsSeptember 13, 2023 | finance.yahoo.comAdaptive Announces Launch of Epic Integration for clonoSEQ®September 12, 2023 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Adaptive Biotechnologies (ADPT)September 11, 2023 | technews.tmcnet.comPlanview Named a Leader in the 2023 Gartner® Magic Quadrant™ for Adaptive Project Management and ReportingSeptember 8, 2023 | msn.comVictrola vinyl decks turn to aptX Adaptive for Hi-Res Audio streamingSeptember 6, 2023 | axios.comAdaptive surfers compete in championship in OceansideSee More Headlines Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2023Today12/01/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADPT CUSIPN/A CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees790Year Founded2009Price Target and Rating Average Stock Price Target$9.50 High Stock Price Target$15.00 Low Stock Price Target$6.00 Potential Upside/Downside+116.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-200,190,000.00 Net Margins-109.04% Pretax Margin-109.08% Return on Equity-47.63% Return on Assets-25.04% Debt Debt-to-Equity RatioN/A Current Ratio4.66 Quick Ratio4.46 Sales & Book Value Annual Sales$185.31 million Price / Sales3.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book1.75Miscellaneous Outstanding Shares144,770,000Free Float137,245,000Market Cap$634.09 million OptionableNot Optionable Beta1.28 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Chad M. Robins M.B.A. (Age 49)Co-Founder, CEO & Chairman Comp: $1.19MMs. Julie Rubinstein (Age 51)President & COO Comp: $760.46kDr. Harlan S. Robins Ph.D. (Age 50)Co-Founder & Chief Scientific Officer Comp: $759.61kMr. Tycho W. Peterson (Age 50)Chief Financial Officer Comp: $539.73kMr. Kyle Piskel (Age 39)VP & Principal Accounting Officer Comp: $375.9kDr. Sharon Benzeno Ph.D. (Age 49)Chief Commercial Officer of Immune Medicine Comp: $671.29kMr. Christopher Carlson Ph.D.FounderMr. Yi ZhouChief Technical OfficerKarina CalzadillaVice President of Investor RelationsMs. Stacy L. Taylor (Age 63)Senior VP, General Counsel & Corporate Secretary More ExecutivesKey CompetitorsAmbrx BiopharmaNYSE:AMAMImmaticsNASDAQ:IMTXHilleVaxNASDAQ:HLVXCabaletta BioNASDAQ:CABANovavaxNASDAQ:NVAXView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 86,478 shares on 11/30/2023Ownership: 0.569%Deutsche Bank AGSold 540,190 shares on 11/24/2023Ownership: 0.039%Kyle PiskelSold 259 sharesTotal: $1,069.67 ($4.13/share)Creative PlanningSold 8,407 shares on 11/16/2023Ownership: 0.014%AQR Capital Management LLCSold 12,449 shares on 11/15/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions ADPT Stock Analysis - Frequently Asked Questions Should I buy or sell Adaptive Biotechnologies stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADPT, but not buy additional shares or sell existing shares. View ADPT analyst ratings or view top-rated stocks. What is Adaptive Biotechnologies' stock price target for 2024? 5 brokers have issued 1-year target prices for Adaptive Biotechnologies' shares. Their ADPT share price targets range from $6.00 to $15.00. On average, they predict the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 116.9% from the stock's current price. View analysts price targets for ADPT or view top-rated stocks among Wall Street analysts. How have ADPT shares performed in 2023? Adaptive Biotechnologies' stock was trading at $7.64 on January 1st, 2023. Since then, ADPT shares have decreased by 42.7% and is now trading at $4.38. View the best growth stocks for 2023 here. When is Adaptive Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our ADPT earnings forecast. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.33) EPS for the quarter, hitting analysts' consensus estimates of ($0.33). The business earned $48.93 million during the quarter, compared to the consensus estimate of $44.87 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 47.63% and a negative net margin of 109.04%. The firm's quarterly revenue was up 12.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.37) EPS. What ETFs hold Adaptive Biotechnologies' stock? ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and ETFMG Treatments Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO? 51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA). When did Adaptive Biotechnologies IPO? (ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Adaptive Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.96%), Sumitomo Mitsui Trust Holdings Inc. (4.54%), Massachusetts Financial Services Co. MA (1.36%), Federated Hermes Inc. (0.96%), Principal Financial Group Inc. (0.86%) and Northern Trust Corp (0.72%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, Nitin Sood, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor and Tycho Peterson. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ADPT) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.